Physician profile
Roy M Koga
NPI 1164511309
$19,660.49
in general payments reported to CMS, 2019-2025
29 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,628 · 2020: $3,082 · 2021: $3,924 · 2022: $3,544 · 2023: $2,639 · 2024: $1,705 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,481.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,540.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,131.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $1,437.94 | 2019-2023 | |
| Amgen INC. | $1,323.01 | 2019-2025 | Repatha, Evenity, Tavneos |
| Lilly USA, LLC | $1,305.38 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $1,235.42 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $997.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $914.77 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $817.34 | 2019-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $719.08 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $654.41 | 2019-2023 | |
| Corcept Therapeutics | $590.01 | 2020-2022 | |
| Abbvie INC. | $526.95 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $468.33 | 2019-2023 | Verquvo |
| Biohaven Pharmaceuticals, INC. | $277.65 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $249.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $223.74 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.85 | 2024 | Caplyta |
| Allergan, INC. | $183.06 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.26 | 2019-2023 | Trintellix |
| Eisai INC. | $159.00 | 2020-2022 | |
| Esperion Therapeutics, INC. | $130.79 | 2020-2025 | Nexletol |
| Horizon Therapeutics Plc | $106.61 | 2021-2022 | |
| Dexcom, INC. | $94.20 | 2023 | Dexcom G7 Gss (161) |
| Otsuka America Pharmaceutical, INC. | $61.16 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $55.40 | 2021-2022 | |
| Boston Scientific Corporation | $36.61 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Koga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.